Posttransplantation Conversion to Sirolimus-Based Immunosuppression: A Single Center Experience

Transplantation Proceedings

Volumn 39, Issue 10, 2007, Pages 3098-3100

  Saber, L T Santamaria ^a   Ikeda, M Y ^a   Almeida, J M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW TOXICITY; CAUSE OF DEATH; CHRONIC ALLOGRAFT NEPHROPATHY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRAFT FAILURE; HERPES SIMPLEX; HERPES ZOSTER; HISTOPLASMOSIS; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE DISORDER; LEUKOPENIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOUTH LESION; MYOPATHY; NEPHROTOXICITY; NEUROCYSTICERCOSIS; NEUROTOXICITY; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RECIPIENT; TUBERCULOSIS; URINARY TRACT INFECTION;

AZATHIOPRINE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SIROLIMUS; TACROLIMUS; TREATMENT OUTCOME;

EID: 37049017772     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.04.021     Document Type: Article

References (20)

1. Seghal S.N., Molnar-Kimber K., Okain T.D., et al. Rapamycin: a novel immunosuppressive macrolide. Med Res Rev 14 (1994) 1
2. Seghal S.N. Sirolimus: its discovery, biological properties and mechanism of action. Transplant Proc 35 (2003) 7S
3. Kreis H.A., and Ponticelli C. Causes of late renal allograft loss: chronic allograft dysfunction, death, and other factors. Transplantation 71 (2001) SS5
4. Pascual M., Theruvath T., Kawai T., et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 346 (2002) 580
5. Nankivell B.J., Borrows R.J., and Chir B. The natural history of chronic allograft nephropathy. N Engl J Med 349 (2003) 2326
6. McKane W., Kanganas C., and Preston R. Treatment of calcineurin inhibitor toxicity by dose reduction plus introduction of mycophenolate mofetil. Transplant Proc 33 (2001) 1224
7. Vincenti F., Ramos E., and Brattstrom C. Multicenter trial exploring calcineurin inhibitor avoidance in renal transplantation. Transplantation 71 (2001) 1282
8. Tierce J.C., Porterfield-Baxa J., Petrilla A.A., et al. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients. Clin Transpl 19 (2005) 779
9. Knoll G.A., McDonald I., Khan A., et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 14 (2003) 2381
10. Diekmann F., and Campistol J.M. Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks. Nephrol Dial Transplant 21 (2006) 562
11. Martinez-Mier G., Mendez-Lopez M.T., and Estrada-Oros J. Conversion from calcineurin inhibitor to sirolimus for renal function deterioration in kidney allograft recipients. Arch Med Res 37 (2006) 635
12. Chapman J.R., O'Connel P.J., and Nankivell B.J. Chronic renal allograft dysfunction. J Am Soc Nephrol 16 (2005) 3015
13. Dominguez J., Mahalati K., and Kiberd B. Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. Transplantation 70 (2000) 1244
14. Egidi M.F., Cowan P.A., Naseer A., et al. Conversion to sirolimus in solid organ transplantation: a single center experience. Transplant Proc 35 (2003) 131S
15. Peddi V.R., Jensik S., and Pescovitz M. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency. Clin Transpl 19 (2005) 130
16. Weber T., Abendroth D., and Schelzig H. Rapamycin rescue therapy in patients after kidney transplantation: first clinical experience. Transpl Int 18 (2005) 151
17. Wu M.-S., Chang C.-T., and Hung C.-C. Rapamycin in patients with chronic renal allograft dysfunction. Clin Transpl 19 (2005) 236
18. Bumbea V., Kamar N., and Ribes D. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 20 (2005) 2517
19. Diekmann F., Budde K., and Oppenheimer F. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 4 (2004) 1869
20. Watson C.J.E., Firth J., and Williams P.F. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 5 (2005) 2496